GlobeNewswire

Invivoscribe Releases the LymphoTrack Dx TRB Assay as CE-Marked IVD Kit, Completing the NGS Clonality Suite for the MiSeq Platform

Del

SAN DIEGO, May 15, 2018 (GLOBE NEWSWIRE) -- Invivoscribe Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized molecular medicine, today announced the release of the LymphoTrack® Dx TRB Assay for the Illumina® MiSeq® platform, a CE-marked next-generation sequencing (NGS) assay kit for in vitro diagnostic (IVD) use. Invivoscribe is the only company offering a complete suite of CE-marked NGS clonality assays designed to assess clonality for both diagnostic and tracking purposes. The LymphoTrack Dx TRB Assay for the ThermoFisher Scientific® Ion PGM(TM) and Ion S5(TM) instruments will be released later this year.

Leukemias and lymphomas generally originate from the malignant transformation of individual lymphoid cells, causing the vast majority of lymphoid malignancies to share one or more cell-specific or "clonal" rearrangements. The LymphoTrack Dx TRB assay identifies clonal TRB VB-(DB-)JB rearrangement sequences, and the accompanying LymphoTrack Dx bioinformatics software provides a clear summary of the frequency distribution. These clonal sequences can be used to monitor minimal residual disease (MRD) in longitudinal studies, which track the disease as well as the effectiveness of therapies aimed towards their eradication.

The LymphoTrack Dx TRB Assay completes the menu of Invivoscribe's CE-marked clonality assays on the MiSeq®, leveraging the unparalleled accuracy and sensitivity of next generation sequencing (NGS), enabling small and large laboratories alike to identify and track clonal rearrangements. Invivoscribe's CE-marked clonality kits, which allow single step PCR library generation and come with bioinformatics software designed to run on standard Windows platforms within customer laboratories, allow for comprehensive multiplex testing of any combination of samples and LymphoTrack Dx assays (e.g. IGH Leader, IGH FR1, IGH FR2, IGH FR3, IGKTRG, and TRB), thus significantly reducing both laboratory costs and turnaround times. Deep-sequencing NGS assays represent a significant improvement over existing PCR-based assays. They accurately identify the majority of gene rearrangement sequences, or clonotypes, which can subsequently be used for MRD tracking. Each kit includes user-friendly LymphoTrack Dx MiSeq® software that automates the sorting and tracking of each sample and target, interprets sequence data, and generates detailed reports.

"We are pleased to offer the first commercially available NGS CE-marked IVD TRB kit, with bioinformatics software, for clonality assessment and tracking. Innovative products like our NGS-based LymphoTrack Dx Assays directly benefit patients by guiding precision treatments and enabling exceptionally sensitive monitoring for disease reoccurrence," said Dr. Jeffrey Miller, CSO and CEO of Invivoscribe.

About Invivoscribe

Invivoscribe Technologies, Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the fields of personalized molecular diagnostics and personalized molecular medicine. The extensive product portfolio includes RUO test kits, CE-marked IVDs, including IdentiClone®, LeukoStrat® and LymphoTrack Dx Assays with LymphoTrack Dx Software to assess clonality, somatic hypermutation and monitor MRD. Invivoscribe's PCR and NGS-based tests, reagents and bioinformatics tools are currently being used in more than 700 clinical and research laboratories in more than 160 countries. Invivoscribe currently has clinical laboratories located in the U.S.A., Europe and Japan which provide international access to harmonized CLIA, CAP, and ISO 15189 accredited clinical testing and contract research organization (CRO) services. Invivoscribe's clinical laboratories also offer comprehensive MyAML®, MyHeme®, MyMRD®, and custom gene panels, that when used in combination with Invivoscribe's proprietary MyInformatics(TM) Software can identify and track primary driver mutations as well as the subclonal architecture and emergence of new driver mutations in patients with hematologic disease. Invivoscribe also has a subsidiary in Shanghai, China that is now supporting clinical trial work in China. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies developing and commercializing companion diagnostics. As a world leader, Invivoscribe has long embraced the value of quality systems, and develops all innovative products, including bioinformatics software in compliance with ISO 13485 design controls, making them eligible to be submitted to worldwide regulatory authorities for registration. 

For additional information please visit www.invivoscribe.com.

CONTACT:
Kevin Dobyns 858-224-6600




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Invivoscribe, Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

PubMatic Launches OpenBid, Bringing Full Strength of Programmatic Monetization to the Mobile App Environment21.2.2019 15:00:00Pressemelding

The Programmatic-First SDK Offers App Developers Benefits of Header Bidding REDWOOD CITY, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today announced the launch of OpenBid, a breakthrough programmatic-first solution that provides app publishers and developers with a gateway to programmatic demand and brand ad budgets. Consumers globally are increasingly interacting with media via mobile devices, and many brand advertisers are turning to in-app advertising to reach this highly-engaged audience. Many are focusing their budgets on automated buying channels such as the open exchange and private marketplaces, with over 90 percent of global media buyers planning to increase their programmatic direct in-app budgets in 2019 (Forrester Consulting). However, many app developers have been unable to fully capitalize on the growing interest from brand advertisers as they rely on legacy mobile mediation partners

Intrinsyc Announces Immediate Availability of Premium-Tier System on Module based on Qualcomm Technologies’ SDA83521.2.2019 13:30:00Pressemelding

Designed for use in XR Applications, IP Cameras, Enterprise Tablets, Medical Imaging, and other Next-Generation IoT Devices VANCOUVER, British Columbia, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Intrinsyc Technologies Corporation (TSX: ITC and OTCQX: ISYRF) (“Intrinsyc” or the “Company”), a leading provider of solutions for the development and production of embedded and Internet of Things (IoT) products, today announced the availability of the Open-Q™ 835 µSOM (micro System on Module) and Development Kit. Intrinsyc’s Open-Q™ 835 µSOM is an ultra-compact (50mm x 25mm) production-ready embedded computing module that is ideal for powering premium performance IoT devices. It is powered by the Qualcomm® SDA835 system on chip (SoC) from Qualcomm Technologies, Inc. “Intrinsyc’s Open-Q™ 835 µSOM is Intrinsyc’s most advanced embedded computing module; enabling the highest combination of computing performance, thermal efficiency and power optimization,” said Cliff Morton, Vice President, Solutions Engin

IMImobile releases unified RCS Messaging API to accelerate RCS adoption for enterprise customer communications21.2.2019 11:09:00Pressemelding

Unified RCS Messaging API and low-code toolset available in IMImobile’s enterprise cloud communications platform IMIconnect will enable businesses to launch RCS customer journeys up to 10 times faster LONDON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Global cloud communications software and solutions provider IMImobile PLC, today releases a unified RCS Messaging API alongside its low-code toolset, in its enterprise cloud communications platform, IMIconnect, to drive the adoption of RCS business messaging by leading enterprises globally. Rich Communication Service (RCS) has been widely anticipated as the evolution for SMS messaging to deliver rich customer experiences to today’s digitally savvy consumers. According to Mobilesquared, there will be 1.01bn people using RCS messaging across 168 mobile operators globally by the end of 2019. This is expected to grow to 3.23bn across 486 mobile operators by the end of 2023.1 With the release of its unified RCS API in the IMIconnect platform, enterpris

Tenaris Announces 2018 Fourth Quarter and Annual Results20.2.2019 22:29:00Pressemelding

The financial and operational information contained in this press release is based on audited consolidated financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Net cash / debt and Free Cash Flow. See exhibit I for more details on these alternative performance measures. LUXEMBOURG, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE, Buenos Aires and Mexico: TS and MTA Italy: TEN) (“Tenaris”) today announced its results for the fourth quarter and year ended December 31, 2018 with comparison to its results for the fourth quarter and year ended December 31, 2017. Summary of 2018 Fourth Quarter Results (Comparison with third quarter of 2018 and fourth quarter of 2017) 4Q 2018 3Q 2018 4Q 2017 Net sales ($ million) 2,105 1,899

New Samsung Galaxy Ultrasonic Fingerprint System World’s First to Achieve FIDO Biometric Certification20.2.2019 21:30:00Pressemelding

Samsung’s new “in-display” Ultrasonic Fingerprint system certified by FIDO Alliance as meeting globally recognized standards for biometric recognition performance and Presentation Attack Detection (PAD) MOUNTAIN VIEW, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- The FIDO Alliance announced today that the Samsung Galaxy S10 and S10+ smartphones are the first products to feature certification from the FIDO Alliance’s new Biometric Component Certification Program. This certification validates that the new in-display fingerprint recognition system meets industry standards for user verification and detecting presentation (or “spoof”) attacks. “As mobile devices increasingly become our primary means of storing sensitive information and conducting critical transactions, the industry leaders in FIDO Alliance have determined the market needs a standard-based means to assess the efficacy of biometric certification components -- which is why we recently launched our Biometric Component Certification

Infovista Expands 5G Network Testing and Planning Capabilities20.2.2019 15:00:00Pressemelding

ASHBURN, Va., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new versions of its TEMS Investigation and Planet solutions. With this announcement, Infovista is the only vendor offering the complete 5G portfolio comprising full network planning and testing in a single, integrated platform. Infovista is now uniquely positioned to help mobile network operators roll out 5G NR networks by including the ability to provide integrated Geodata, 5G Planning and Network Testing capabilities. Tweet This: @Infovista expands 5G network testing and planning capabilities, offering complete 5G portfolio in a single, integrated platform: https://bit.ly/2Nm8Rup With the new release of TEMS Investigation, Infovista introduces support for 5G smartphones based on the Qualcomm X50 chipset. With initial support of Qualcomm based devices and plans for agnostic device support, customers will be able to choose between different test devices and scanners to s